Converging on an HIV Vaccine
According to Bette Korber and S. Gnanakaran in their work of converging on an HIV vaccine, they talk about how the HIV virus attacks the body and how it can be suppressed. This work was first introduced on 19th September of 2011. They start of by saying that even after 3 full decades there hasn’t been a discovery of vaccine for HIV, also known as the human immunodeficiency virus. Even though Multidrug therapy can extend one’s life and health for those with HIV virus, it can’t really save a person’s life. Therefore, a vaccination is important for the treatment of these sick people.
Broadly neutralizing antibodies (BNAbs) can block the HIV infection from infecting target T cells and so it has the potential of preventing new infections. They also say that Nabs can block HIV infections, but making a vaccine that has the same result had been difficult. BNAbs only show up in little amount of people that are infected by HIV but that happens only after a substantial delay. Also efficacy trials that tried to activate protective antibodies for defense against this HIV virus either failed or showed only a little amount of protection. Therefore, trying to treat people that are infected with HIV with this HIV Envelope either failed or showed a tiny bit of protection.
Since this method doesn’t work on treating HIV another approach suggested was the shared characteristics of a class of potent BNAbs that binds to the CD4 binding site of the heavy and the light chains that constitute each antibody. Elements from different parts of gene regions come together to make the heavy and the light chains, which allows a huge array of combinatorial possibilities. Also they tell us that each antibody carries a complementarity determining region that compliments an epitope on a target protein. So the B cells, which produce B cells begins to destroy